

Supporting Information

Table S1. Search Strategy

Table S2. The Newcastle-Ottawa Scale Summary for Each Observational Study

Figure S1. Risk of Bias Summary for Each Randomized Clinical Trial

Figure S2. Risk of Bias Graph for Each Randomized Clinical Trial

Figure S3. GRADE Summary of Findings

Figure S4. Forest Plot of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days

Figure S5. Forest Plot of Subgroup Analysis by the Time of Administration of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days

Figure S6. Forest Plot of Subgroup Analysis by the Time of Administration of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days

Figure S7. Forest Plot of Subgroup Analysis by Various Antiplatelet Therapies of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days

Figure S8. Forest Plot of Subgroup Analysis by Various Antiplatelet Therapies of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days

Figure S9. Forest Plot of Subgroup Analysis by Etiologies of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days

Figure S10. Forest Plot of Sensitivity Analysis of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days

Figure S11. Forest Plot of Sensitivity Analysis of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days

Figure S12. Forest Plot of Antiplatelet Therapy versus IVT on Stroke Recurrence within 90 Days

Table S1. Search Strategy

Search number	Query
1	((((((((((((((((((((((Ischemic stroke[MeSH Terms]) OR (Ischemic Strokes[Title/Abstract])) OR (Stroke, Ischemic[Title/Abstract])) OR (Ischaemic Stroke[Title/Abstract])) OR (Ischaemic Strokes[Title/Abstract])) OR (Stroke, Ischaemic[Title/Abstract])) OR (Cryptogenic Ischemic Stroke[Title/Abstract])) OR (Cryptogenic Ischemic Strokes[Title/Abstract])) OR (Ischemic Stroke, Cryptogenic[Title/Abstract])) OR (Stroke, Cryptogenic Ischemic[Title/Abstract])) OR (Cryptogenic Stroke[Title/Abstract])) OR (Cryptogenic Strokes[Title/Abstract])) OR (Stroke, Cryptogenic[Title/Abstract])) OR (Cryptogenic Embolism Stroke[Title/Abstract])) OR (Cryptogenic Embolism Strokes[Title/Abstract])) OR (Embolism Stroke, Cryptogenic[Title/Abstract])) OR (Stroke, Cryptogenic Embolism[Title/Abstract])) OR (Wake-up Stroke[Title/Abstract])) OR (Stroke, Wake-up[Title/Abstract])) OR (Wake up Stroke[Title/Abstract])) OR (Wake-up Strokes[Title/Abstract])) OR (Acute Ischemic Stroke[Title/Abstract])) OR (Acute Ischemic Strokes[Title/Abstract])) OR (Ischemic Stroke, Acute[Title/Abstract])) OR (Stroke, Acute Ischemic[Title/Abstract])) OR (ischemic stroke[Title/Abstract])
2	((((((((((((((((((((((Brain ischemia[MeSH Terms]) OR (Brain Ischemias[Title/Abstract])) OR (Ischemia, Brain[Title/Abstract])) OR (Ischemic Encephalopathy[Title/Abstract])) OR (Encephalopathy, Ischemic[Title/Abstract])) OR (Ischemic Encephalopathies[Title/Abstract])) OR (Cerebral Ischemia[Title/Abstract])) OR (Cerebral Ischemias[Title/Abstract])) OR (Ischemias, Cerebral[Title/Abstract])) OR (Ischemia, Cerebral[Title/Abstract])) OR (Brain isch?m*[Title/Abstract])) OR (Cerebral isch?m*[Title/Abstract])) OR (brain ischemia[Title/Abstract])
3	((((((((((((((((((((((Cerebral infarction[MeSH Terms]) OR (Cerebral Infarctions[Title/Abstract])) OR (Infarctions, Cerebral[Title/Abstract])) OR (Infarction, Cerebral[Title/Abstract])) OR (Cerebral Infarct[Title/Abstract])) OR (Cerebral Infarcts[Title/Abstract])) OR (Infarct, Cerebral[Title/Abstract])) OR (Infarcts, Cerebral[Title/Abstract])) OR (Cerebral Infarction, Left Hemisphere[Title/Abstract])) OR (Left Hemisphere, Infarction, Cerebral[Title/Abstract])) OR (Infarction, Left Hemisphere, Cerebral[Title/Abstract])) OR (Left Hemisphere, Cerebral Infarction[Title/Abstract])) OR (Cerebral, Left Hemisphere, Infarction[Title/Abstract])) OR (Infarction, Cerebral, Left Hemisphere[Title/Abstract])) OR (Subcortical Infarction[Title/Abstract])) OR (Infarction, Subcortical[Title/Abstract])) OR (Infarctions, Subcortical[Title/Abstract])) OR (Subcortical Infarctions[Title/Abstract])) OR (Posterior Choroidal Artery Infarction[Title/Abstract])) OR (Anterior Choroidal Artery Infarction[Title/Abstract])) OR (Cerebral Infarction, Right Hemisphere[Title/Abstract])) OR (Right Hemisphere, Cerebral

	Infarction[Title/Abstract])) OR (Infarction, Right Hemisphere, Cerebral[Title/Abstract])) OR (Right Hemisphere, Infarction, Cerebral[Title/Abstract])) OR (Cerebral, Right Hemisphere, Infarction[Title/Abstract])) OR (Infarction, Cerebral, Right Hemisphere[Title/Abstract])) OR (Brain infarct*[Title/Abstract])) OR (Cerebral infarct*[Title/Abstract])) OR (cerebral infarction[Title/Abstract]))
4	#1 OR #2 OR #3
5	(((((minor[Title/Abstract])) OR (mild[Title/Abstract])) OR (nondisabling[Title/Abstract])) OR (non disabling[Title/Abstract])) OR (non-disabling[Title/Abstract])) OR (not disabling[Title/Abstract]))
6	#4 AND #5
7	((((((((((((((((((((((((((((((((((((((platelet aggregation inhibitors[MeSH Terms])) OR (Aggregation Inhibitors, Platelet[Title/Abstract])) OR (Inhibitors, Platelet Aggregation[Title/Abstract])) OR (Blood Platelet Antiaggregants[Title/Abstract])) OR (Antiaggregants, Blood Platelet[Title/Abstract])) OR (Antiaggregants, Platelet[Title/Abstract])) OR (Platelet Antiaggregant[Title/Abstract])) OR (Antiaggregant, Platelet[Title/Abstract])) OR (Blood Platelet Aggregation Inhibitor[Title/Abstract])) OR (Blood Platelet Antiaggregant[Title/Abstract])) OR (Antiaggregant, Blood Platelet[Title/Abstract])) OR (Platelet Antiaggregant, Blood[Title/Abstract])) OR (Platelet Aggregation Inhibitor[Title/Abstract])) OR (Aggregation Inhibitor, Platelet[Title/Abstract])) OR (Inhibitor, Platelet Aggregation[Title/Abstract])) OR (Blood Platelet Aggregation Inhibitors[Title/Abstract])) OR (Platelet Antiaggregants[Title/Abstract])) OR (Platelet Inhibitors[Title/Abstract])) OR (Inhibitors, Platelet[Title/Abstract])) OR (Platelet Inhibitor[Title/Abstract])) OR (Inhibitor, Platelet[Title/Abstract])) OR (Antiplatelet Agents[Title/Abstract])) OR (Agents, Antiplatelet[Title/Abstract])) OR (Antiplatelet Agent[Title/Abstract])) OR (Agent, Antiplatelet[Title/Abstract])) OR (Antiplatelet Drug[Title/Abstract])) OR (Drug, Antiplatelet[Title/Abstract])) OR (Antiplatelet Drugs[Title/Abstract])) OR (Drugs, Antiplatelet[Title/Abstract])) OR (Platelet Antagonists[Title/Abstract])) OR (Antagonists, Platelet[Title/Abstract])) OR (Blood Platelet Antagonist[Title/Abstract])) OR (Antagonist, Blood Platelet[Title/Abstract])) OR (Platelet Antagonist, Blood[Title/Abstract])) OR (Platelet Antagonist[Title/Abstract])) OR (Antagonist, Platelet[Title/Abstract])) OR (Blood Platelet Antagonists[Title/Abstract])) OR (Antagonists, Blood Platelet[Title/Abstract])) OR (antiplatelet[Title/Abstract]))
8	((((((((((((((((((((((((((((((((((((((aspirin[MeSH Terms])) OR (Acetylsalicylic Acid[Title/Abstract])) OR (Acid, Acetylsalicylic[Title/Abstract])) OR (2-(Acetyloxy)benzoic Acid[Title/Abstract])) OR (Acylpyrin[Title/Abstract])) OR (Aloxiiprimum[Title/Abstract])) OR (Colfarit[Title/Abstract])) OR (Dispril[Title/Abstract])) OR (Easprin[Title/Abstract])) OR (Ecotrin[Title/Abstract])) OR (Endosprin[Title/Abstract])) OR

	(Magneeryl[Title/Abstract])) OR (Micristin[Title/Abstract])) OR (Polopirin[Title/Abstract])) OR (Polopiryna[Title/Abstract])) OR (Solprin[Title/Abstract])) OR (Solupsan[Title/Abstract])) OR (Zorprin[Title/Abstract])) OR (Acetysal[Title/Abstract]))
9	((((((((((((((((((clopidogrel[MeSH Terms]) OR (SC 25989C[Title/Abstract])) OR (SC 25990C[Title/Abstract])) OR (SR 25989[Title/Abstract])) OR (Clopidogrel-Mepha[Title/Abstract])) OR (Clopidogrel Mepha[Title/Abstract])) OR (Clopidogrel Sandoz[Title/Abstract])) OR (Iscover[Title/Abstract])) OR (Clopidogrel Napadisilate[Title/Abstract])) OR (Clopidogrel Hydrochloride[Title/Abstract])) OR (PCR 4099[Title/Abstract])) OR (PCR-4099[Title/Abstract])) OR (Clopidogrel Besylate[Title/Abstract])) OR (Clopidogrel Besilate[Title/Abstract])) OR (Clopidogrel, (+)(S)-isomer[Title/Abstract])) OR (Plavix[Title/Abstract])) OR (Clopidogrel Bisulfate[Title/Abstract]))
10	((((((((ticagrelor[MeSH Terms]) OR (Brilique[Title/Abstract])) OR (AZD 6140[Title/Abstract])) OR (AZD6140[Title/Abstract])) OR (AZD-6140[Title/Abstract])) OR (Brilinta[Title/Abstract])) OR (3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol[Title/Abstract]))
11	(((((Dual Anti-Platelet Therapy[MeSH Terms]) OR (Anti-Platelet Therapies, Dual[Title/Abstract])) OR (Anti-Platelet Therapy, Dual[Title/Abstract])) OR (Dual Anti Platelet Therapy[Title/Abstract])) OR (Dual Anti-Platelet Therapies[Title/Abstract]))
12	#7 OR #8 OR #9 OR #10 OR #11
13	((((((((((((((((((Tissue Plasminogen Activator[MeSH Terms]) OR (Plasminogen Activator, Tissue[Title/Abstract])) OR (Tissue Activator D-44[Title/Abstract])) OR (Tissue Activator D 44[Title/Abstract])) OR (Tisokinase[Title/Abstract])) OR (Tissue-Type Plasminogen Activator[Title/Abstract])) OR (Tissue Type Plasminogen Activator[Title/Abstract])) OR (TTPA[Title/Abstract])) OR (T-Plasminogen Activator[Title/Abstract])) OR (T Plasminogen Activator[Title/Abstract])) OR (Alteplase[Title/Abstract])) OR (Plasminogen Activator, Tissue-Type[Title/Abstract])) OR (Plasminogen Activator, Tissue Type[Title/Abstract])) OR (Activase[Title/Abstract])) OR (Actilyse[Title/Abstract])) OR (Lysatec rt-PA[Title/Abstract])) OR (Lysatec rt PA[Title/Abstract])) OR (Lysatec rtPA[Title/Abstract]))
14	((Tenecteplase[MeSH Terms]) OR (Metalyse[Title/Abstract])) OR (TNKase[Title/Abstract]))
15	((intravenous thrombolysis[Title/Abstract]) OR (iv thrombolysis[Title/Abstract])) OR (ivt[Title/Abstract]))
16	#13 OR #14 OR #15
17	#6 AND #12 AND #16

Table S2. The Newcastle-Ottawa Scale Summary for Each Observational Study

Basic information	Selection				Comparability	Outcome			Scores
Study ID	Representativeness of the exposed cohort	Selection of the non exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	
Duan 2023	★	★	★	★	★ ★	★	★	★	
Lan 2020	★	★	★	★	★ ★	★	★	★	
Sykora 2023	★	★	★	★	★ ★	★	★	★	
Wang 2021	★	-	★	★	★ ★	★	★	★	8

Figure S1. Risk of Bias Summary for Each Randomized Clinical Trial




Figure S2. Risk of Bias Graph for Each Randomized Clinical Trial




Figure S3. GRADE Summary of Findings

Outcomes	No. of participants (No. of studies)	Certainty assessment						Relative effect (95% CI)	Absolute effect (95% CI)	Certainty
		Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations			
mRS 0-1 RCTs	1032 (2)	RCTs	Serious ^a	Not serious	Not serious	Not serious	None	OR 1.32 (0.89 - 1.95)	28 more per 1,000 (from 13 fewer to 57 more)	⊕⊕⊕ ○ Moderate
mRS 0-1 Cohorts	2537 (4)	Observational studies	Not serious	Not serious	Not serious	Not serious	None	OR 0.99 (0.57 - 1.72)	1 fewer per 1,000 (from 80 fewer to 51 more)	⊕⊕○○ Low
mRS 0-2 RCTs	1032 (2)	RCTs	Serious ^a	Not serious	Not serious	Not serious	None	OR 1.29 (0.75 - 2.20)	14 more per 1,000 (from 19 fewer to 33 more)	⊕⊕⊕ ○ Moderate
mRS 0-2 Cohorts	2225 (3)	Observational studies	Not serious	Not serious	Not serious	Not serious	None	OR 0.93 (0.38 - 2.29)	4 fewer per 1,000 (from 83 fewer to 32 more)	⊕⊕○○ Low
death 0-2 RCTs	1032 (2)	RCTs	Serious ^a	Not serious	Not serious	Not serious	None	OR 0.53 (0.11 - 2.51)	4 fewer per 1,000 (from 7 fewer to 12 more)	⊕⊕⊕ ○ Moderate
death 0-2 Cohorts	1048 (2)	Observational studies	Not serious	Not serious	Not serious	Not serious	None	OR 0.86 (0.12 - 6.17)	1 fewer per 1,000 (from 4 fewer to 20 more)	⊕⊕○○ Low
stroke recurrence RCTs	1032 (2)	RCTs	Serious ^a	Not serious	Not serious	Not serious	None	OR 0.98 (0.34 - 2.84)	0 fewer per 1,000 (from 9 fewer to 24 more)	⊕⊕⊕ ○ Moderate
stroke recurrence	218 (1)	Observational studies	Not serious	Not serious	Not serious	Not serious	None	OR 0.24 (0.03 -	28 fewer per 1,000 (from 36	⊕⊕○○ Low

Cohort s								2.21)	fewer to 41 more)	
								OR	7 fewer	⊕ ⊕ ⊕
sICH RCTs	1036 (2)	RCTs	Seriou s ^a	Not serious	Not serious	Not serious	Strong associati on	0.26 (0.04 - 1.60)	per 1,000 (from 9 fewer to 6 more)	⊕ ⊕ High
sICH Cohort s	936 (2)	Observa tional studies	Not serious	Not serious	Not serious	Not serious	Strong associati on	OR 0.16 (0.03 - 0.89)	16 fewer per 1,000 (from 18 fewer to 2 fewer)	⊕ ⊕ ⊕ ○ Modera te

Abbreviations: Randomized controlled trials (RCTs), modified Rankin Scale (mRS), odds ratio (OR), symptomatic intracranial hemorrhage (sICH).

Explanations:

^aOne of the studies was open-labeled.

Figure S4. Forest Plot of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 days




Figure S5. Forest Plot of Subgroup Analysis by the Time of Administration of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days




Figure S6. Forest Plot of Subgroup Analysis by the Time of Administration of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days




Figure S7. Forest Plot of Subgroup Analysis by Various Antiplatelet Therapies of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days




Figure S8. Forest Plot of Subgroup Analysis by Various Antiplatelet Therapies of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days




Figure S9. Forest Plot of Subgroup Analysis by Etiologies of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days




Figure S10. Forest Plot of Sensitivity Analysis of Antiplatelet Therapy versus IVT on Excellent Functional Outcome at 90 Days




Figure S11. Forest Plot of Sensitivity Analysis of Antiplatelet Therapy versus IVT on Favorable Functional Outcome at 90 Days




Figure S12. Forest Plot of Antiplatelet Therapy versus IVT on Stroke Recurrence within 90 Days

